Between The Lines: Guidelines for Use and Dosing of Selinexor in Multiple Myeloma

home / between-the-lines / between-the-lines-guidelines-for-use-and-dosing-of-selinexor-in-multiple-myeloma

Dr Joshua Richter and Dr Peter Forsberg review key trial data and dosing strategies for selinexor based combinations.

An Overview of Treatment Options Available for Patients with R/R MM

EP. 1: An Overview of Treatment Options Available for Patients with R/R MM

Joshua Richter, MD;Peter Forsberg, MD
October 4th 2022

Opening their discussion on relapsed/refractory multiple myeloma, Joshua Richter, MD and Peter Forsberg, MD review options for treatment sequencing, initiating treatment, and the mechanism of action for selinexor.

Key Trial Data Supporting the Use of Selinexor in Patients with R/R MM

EP. 2: Key Trial Data Supporting the Use of Selinexor in Patients with R/R MM

Joshua Richter, MD;Peter Forsberg, MD
October 4th 2022

Two subject matter experts discuss keystone trials supporting the use of Selinexor in patients with R/R MM, each with unique dosing structures and different selinexor-based combinations.

Dosing Strategies and Adverse Events in Patients Treated with Selinexor

EP. 3: Dosing Strategies and Adverse Events in Patients Treated with Selinexor

Peter Forsberg, MD;Joshua Richter, MD
October 12th 2022

Discourse centered around dosing strategies for selinexor-based therapies.

Practical Considerations for Reducing Risk and Providing Supportive Care

EP. 4: Practical Considerations for Reducing Risk and Providing Supportive Care

Peter Forsberg, MD;Joshua Richter, MD
October 12th 2022

Insights on supportive care measures to minimize or counter common adverse effects for patients with R/R MM taking selinexor-based therapies

Looking Forward: Advice for Clinicians and Discussing Unmet Needs in the R/R MM Landscape

EP. 5: Looking Forward: Advice for Clinicians and Discussing Unmet Needs in the R/R MM Landscape

Peter Forsberg, MD;Joshua Richter, MD
October 19th 2022

Dr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.

Recap: A Review of Selinexor Combination Therapies in Relapsed/Refractory Multiple Myeloma

EP. 6: Recap: A Review of Selinexor Combination Therapies in Relapsed/Refractory Multiple Myeloma

ONCOLOGY Staff
November 15th 2022

In a recent Between the Lines, Joshua Richter, MD, and Peter Forsberg, MD, discussed a recent commentary on weekly dosing and supportive care solutions for selinexor in patients with multiple myeloma, and provided a general overview of the agent in this treatment landscape.